Related Experiment Videos
Controlled release microparticles for vaccine development
D T O'Hagan1, H Jeffery, M J Roberts
1Department of Pharmaceutical Sciences, University of Nottingham, University Park, UK.
Abstract:
The primary and secondary sera IgG antibody responses to ovalbumin (OVA) entrapped in biodegradable poly(lactide-co-glycolide) (PLGA) microparticles were compared with the responses obtained with soluble OVA. In addition, OVA in PLGA microparticles was also administered after dispersion in an immunostimulatory vehicle, Freund's incomplete adjuvant (FIA). The primary IgG responses to OVA in microparticles/FIA were significantly greater than the responses to soluble OVA from day 14 to day 42, when booster immunizations were administered. From day 49 to the end of the study at day 84, the responses to OVA, both in microparticles alone and in microparticles/FIA, were significantly greater than the responses to soluble OVA. Nevertheless, the responses obtained for OVA in microparticles or microparticles/FIA were, in general, not as high as those obtained with OVA in Freund's complete adjuvant.
Insights
Biodegradable poly(lactide-co-glycolide) (PLGA) microparticles enhanced IgG antibody responses to ovalbumin (OVA) compared to soluble OVA. Adjuvant (FIA) further boosted responses, though Freund's complete adjuvant yielded the highest levels.
Area of Science:
- Immunology
- Biomaterials Science
- Vaccine Development
Background:
- Biodegradable microparticles offer a promising platform for antigen delivery.
- Poly(lactide-co-glycolide) (PLGA) microparticles are widely studied for controlled release applications.
- Ovalbumin (OVA) is a model antigen used in immunological studies.
Purpose of the Study:
- To compare IgG antibody responses to ovalbumin (OVA) delivered via PLGA microparticles versus soluble OVA.
- To evaluate the effect of Freund's incomplete adjuvant (FIA) on OVA-loaded PLGA microparticle immunogenicity.
- To assess the long-term antibody response profiles.
Main Methods:
- Rabbits were immunized with OVA encapsulated in PLGA microparticles, with or without FIA, or with soluble OVA.
- Primary and secondary IgG antibody titers against OVA were measured over 84 days.
- Comparisons were made between different delivery formulations and adjuvant combinations.
Main Results:
- OVA in PLGA microparticles, especially with FIA, induced significantly higher primary IgG responses than soluble OVA.
- Sustained elevated IgG responses were observed for microparticle formulations from day 49 to day 84.
- While effective, OVA in PLGA microparticles/FIA generally elicited lower responses than OVA in Freund's complete adjuvant.
Conclusions:
- PLGA microparticles enhance systemic IgG antibody responses to entrapped antigens like OVA.
- The addition of Freund's incomplete adjuvant further potentiates the immune response elicited by microparticle-delivered OVA.
- PLGA microparticles represent a viable strategy for developing subunit vaccines, although adjuvant choice remains critical.